학술논문
Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke The EXTEND-IA TNK Part 2 Randomized Clinical Trial
Research / Original Investigation
Research / Original Investigation
Document Type
Report
Author
Campbell, Bruce C.V.; Mitchell, Peter J.; Churilov, Leonid; Yassi, Nawaf; Kleinig, Timothy J.; Dowling, Richard J.; Yan, Bernard; Bush, Steven J.; Thijs, Vincent; Scroop, Rebecca; Simpson, Marion; Brooks, Mark; Asadi, Hamed; Wu, Teddy Y.; Shah, Darshan G.; Wijeratne, Tissa; Zhao, Henry; Alemseged, Fana; Ng, Felix; Bailey, Peter; Rice, Henry; De Villiers, Laetitia; Dewey, Helen M.; Choi, Philip M.C.; Brown, Helen; Redmond, Kendal; Leggett, David; Fink, John N.; Collecutt, Wayne; Kraemer, Thomas; Krause, Martin; Cordato, Dennis; Field, Deborah; Ma, Henry; O'Brien, Bill; Clissold, Benjamin; Miteff, Ferdinand; Clissold, Anna; Cloud, Geoffrey C.; Bolitho, Leslie E.; Bonavia, Luke; Bhattacharya, Arup; Wright, Alistair; Mamun, Abul; O'Rourke, Fintan; Worthington, John; Wong, Andrew A.; Levi, Christopher R.; Bladin, Christopher F.; Sharma, Gagan; Desmond, Patricia M.; Parsons, Mark W.; Donnan, Geoffrey A.; Davis, Stephen M.
Source
JAMA, The Journal of the American Medical Association. April 7, 2020, Vol. 323 Issue 13, p1257, 9 p.
Subject
Language
English
ISSN
0098-7484
Abstract
The 0.40-mg/kg dose of tenecteplase may not confer an advantage over the 0.25-mg/kg dose in patients with large vessel occlusion ischemic stroke. In 300 adults, the percentage who achieved substantial reperfusion prior to endovascular thrombectomy was 19.3% in each tenecteplase dose group, with no statistically significant difference.